divergent-paired related homeobox pseudogene 5Genealiases: []
Q-omics provides the consensus-scored DPRXP5 profile across patient tissues and cancer cell-line models. DPRXP5 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DPRXP5 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, DPRXP5 RNA expression shows 6,558 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, THCA, and STAD as cancer lineages where DPRXP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPRXP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPRXP5 survival associations across molecular data types. DPRXP5 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPRXP5 RNA expression–survival associations across cancer types. High DPRXP5 expression shows unfavorable associations in BLCA, ESCA, KIRC, ACC and PAAD, but favorable associations in OV. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify BLCA as the clearest survival context for DPRXP5 RNA expression.
This table summarizes DPRXP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPRXP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPRXP5 shows lower tumor expression in THCA and higher tumor expression in LIHC and LUAD. The THCA box plot shows higher DPRXP5 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .008).
This table shows molecular features associated with DPRXP5 in patient tissues and cancer cell lines. In patient samples, DPRXP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
